TheraVet SA (ALVET.PA)
EUR 0.11
(-0.46%)
EUR 0.11
(-0.46%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.17 Million EUR | 14.56% |
| 2022 | -2.77 Million EUR | -60.6% |
| 2021 | -1.72 Million EUR | -330.94% |
| 2020 | -401.2 Thousand EUR | -320.87% |
| 2019 | -95.32 Thousand EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -482.13 Thousand EUR | 0.0% |
| 2024 Q1 | -482.13 Thousand EUR | -12.65% |
| 2023 Q2 | -1.31 Million EUR | -99.44% |
| 2023 Q1 | -659.57 Thousand EUR | 57.74% |
| 2023 Q4 | -427.97 Thousand EUR | 0.0% |
| 2023 Q3 | -427.97 Thousand EUR | 67.47% |
| 2023 FY | -2.37 Million EUR | 14.56% |
| 2022 Q1 | -682.32 Thousand EUR | 9.08% |
| 2022 Q3 | -706.02 Thousand EUR | 41.93% |
| 2022 Q4 | -1.56 Million EUR | -121.07% |
| 2022 FY | -2.77 Million EUR | -60.6% |
| 2022 Q2 | -1.21 Million EUR | -78.2% |
| 2021 Q1 | -546.75 Thousand EUR | -3.45% |
| 2021 Q3 | -317.7 Thousand EUR | 60.68% |
| 2021 Q2 | -807.97 Thousand EUR | -47.78% |
| 2021 FY | -1.72 Million EUR | -330.94% |
| 2021 Q4 | -750.45 Thousand EUR | -136.21% |
| 2020 Q4 | -528.51 Thousand EUR | -307.93% |
| 2020 Q3 | -129.55 Thousand EUR | 8.82% |
| 2020 Q2 | -142.09 Thousand EUR | -100.01% |
| 2020 FY | -401.2 Thousand EUR | -320.87% |
| 2020 Q1 | -71.04 Thousand EUR | 0.0% |
| 2019 FY | -95.32 Thousand EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | 36.251% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 98.292% |
| Adocia SA | -17.62 Million EUR | 87.657% |
| Aelis Farma SA | -6.46 Million EUR | 66.335% |
| Biophytis S.A. | -14.33 Million EUR | 84.824% |
| Advicenne S.A. | -6.45 Million EUR | 66.314% |
| genOway Société anonyme | 2.06 Million EUR | 205.317% |
| IntegraGen SA | -183.77 Thousand EUR | -1083.604% |
| Medesis Pharma S.A. | -4.22 Million EUR | 48.571% |
| Neovacs S.A. | -6.9 Million EUR | 68.511% |
| NFL Biosciences SA | -4.43 Million EUR | 50.905% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -179.492% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | 30.668% |
| Sensorion SA | -22.31 Million EUR | 90.251% |
| Theranexus Société Anonyme | -7.64 Million EUR | 71.544% |
| TME Pharma N.V. | -5.62 Million EUR | 61.325% |
| Valbiotis SA | -7.16 Million EUR | 69.621% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 89.279% |
| argenx SE | -417.15 Million EUR | 99.479% |
| BioSenic S.A. | -7.04 Million EUR | 69.104% |
| Celyad Oncology SA | -8.45 Million EUR | 74.28% |
| DBV Technologies S.A. | -85.24 Million EUR | 97.448% |
| Galapagos NV | -88.26 Million EUR | 97.536% |
| Genfit S.A. | -26.58 Million EUR | 91.817% |
| GeNeuro SA | -14.35 Million EUR | 84.85% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 86.4% |
| Innate Pharma S.A. | -12.66 Million EUR | 82.831% |
| Inventiva S.A. | -102.7 Million EUR | 97.882% |
| MaaT Pharma SA | -19.94 Million EUR | 89.093% |
| MedinCell S.A. | -20.97 Million EUR | 89.631% |
| Nanobiotix S.A. | -26.77 Million EUR | 91.878% |
| Onward Medical N.V. | -35.46 Million EUR | 93.867% |
| Oryzon Genomics S.A. | -4.54 Million EUR | 52.187% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 90.537% |
| Oxurion NV | -12.11 Million EUR | 82.039% |
| Pharming Group N.V. | -4.87 Million EUR | 55.424% |
| Poxel S.A. | -28.76 Million EUR | 92.438% |
| GenSight Biologics S.A. | -29.69 Million EUR | 92.675% |
| Transgene SA | -30.01 Million EUR | 92.753% |
| Financière de Tubize SA | -2.14 Million EUR | -1.452% |
| UCB SA | 604 Million EUR | 100.36% |
| Valneva SE | -82.08 Million EUR | 97.35% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 92.457% |